Release Date: 2024-05-28
Adjuvant Intravesical Chemotherapy
Ilkin Hamid-Zada (Author), Kenan Toprak (Author)
Release Date: 2024-05-28
In this section, we reviewed adjuvant intravesical chemotherapy for Non-Muscle invasive bladder cancer. Mitomycin C indicated for the treatment of bladder cancer and effective for low and intermediate-risk tumors.Epirubicin is a doxorubicin analogue. Perioperative epirubicin treatment is appropriate for patients with low-grade ,single sided and up to 3 cm diameter tumors. Gemcitabine is a chemotherapeutic [...]
Media Type
PDF
Buy from
Price may vary by retailers
| Work Type | Book Chapter |
|---|---|
| Published in | Current Management of Non-Muscle Invasive Bladder Cancer |
| First Page | 133 |
| Last Page | 142 |
| DOI | https://doi.org/10.69860/nobel.9786053359197.11 |
| ISBN | 978-605-335-919-7 (PDF) |
| Language | ENG |
| Page Count | 10 |
| Copyright Holder | Nobel Tıp Kitabevleri |
| License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Ilkin Hamid-Zada (Author)
Istanbul Medeniyet University
https://orcid.org/0009-0000-0550-250X
3Ilkin Hamid-zada works as a urology resident in the Urology Department of Istanbul Medeniyet University. He participated in many congresses and scientific studies. He is particularly interested in the field of uro-oncology.
Kenan Toprak (Author)
MD, Gaziantep Nizip State Hospital
https://orcid.org/0000-0002-8243-6777
3Kenan Toprak was born in 1986,in Gaziantep,Turkey.He graduated from Cerrahpaşa Medical Faculty English program in 2011.He completed his medical specialization education at Istanbul Medeniyet University, Göztepe Training and Research Hospital in 2021 and became a urology specialist.He did his compulsory service at Muş State Hospital.He has contributed to several scientific studies, book chapters, and academic assignments. He currently works as a urologist at Gaziantep Nizip State Hospital.
1. Volpe A, Racioppi M, D’Agostino D, Cappa E, Filianoti A, Bassi PF. Mitomycin C for the treatment of bladder cancer. Minerva Urol Nefrol. 2010 Jun;62(2):133-44.
2. Charpentier X, Kay E, Schneider D, Shuman HA. Antibiotics and UV radiation induce competence for natural transformation in Legionella pneumophila. J Bacteriol. 2011 Mar;193(5):1114-21. doi: 10.1128/JB.01146-10. Epub 2010 Dec 17.
3. Tomasz M. Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995 Sep;2(9):575-9.
4. Sturm JB, Hess M, Weibel S, Chen NG, Yu YA, Zhang Q, et al. Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy. J Transl Med. 2012 Jan 11;10:9.
5. Filson CP, Montgomery JS, Dailey SM, Crossley HS, Lentz H, Tallman CT, et al. Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. Urol Oncol. 2014 Jan;32(1):40.e1-8.
6. Zargar H, Aning J, Ischia J, So A, Black P. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014 Apr;11(4):220- 30.
7. Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, et al. International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18;93(8):597-604
8. Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. 2016 Feb;69(2):231-44.
9. Racioppi M, Volpe A, Cappa E, D’Agostino D, Pinto F, D’Addessi A, et al. Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach. Urol Int. 2010;85(3):266-9.
10. De Nunzio C, Carbone A, Albisinni S, Alpi G, Cantiani A, Liberti M, et al. Longterm experience with early single mitomycin C instillations in patients with lowrisk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. World J Urol. 2011 Aug;29(4):517-21.
11. Bahouth Z, Halachmi S, Moskovitz B, Nativ O. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer. Expert Rev Anticancer Ther. 2016;16(2):189-98.
12. Sooriakumaran P, Chiocchia V, Dutton S, Pai A, Ayres BE, Le Roux P, et al. Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients. Urol Int. 2016;96(1):83-90.
13. Ba M, Cui S, Wang B, Long H, Yan Z, Wang S, Wu Y, Gong Y. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection. Oncol Rep. 2017 May;37(5):2761-2770
14. Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009 Jun;27(3):319-24
15. Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011 Mar;107(6):912-8.
16. Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol. 2005 Apr;16(4):585-9.
17. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004 Jun;171(6 Pt 1):2186-90, quiz 2435.
18. Gudjónsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009 Apr;55(4):773-80.
19. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al. EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010 May;57(5):766-73.
20. Gudjónsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009 Apr;55(4):773-80.
21. Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol. 2014 Oct;66(4):694-701.
22. Perdonà S, Di Lorenzo G, Cantiello F, Damiano R, De Sio M, Masala D, et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010 Jan;21(1):101-6.
23. Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Intravesical gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol. 2008 Nov-Dec;26(6):616-9.
24. Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. Urol Int. 2005;75(4):309-13.
25. Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010 Sep-Oct;28(5):510-4.
26. Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006 Jun 20;24(18):2729-34.
27. Cookson MS, Chang SS, Lihou C, Li T, Harper SQ, Lang Z, Tutrone RF. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol. 2014 Oct;6(5):181-91.
28. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–7.
| onix_3.0::thoth | Thoth ONIX 3.0 |
|---|---|
| onix_3.0::project_muse | Project MUSE ONIX 3.0 |
| onix_3.0::oapen | OAPEN ONIX 3.0 |
| onix_3.0::jstor | JSTOR ONIX 3.0 |
| onix_3.0::google_books | Google Books ONIX 3.0 |
| onix_3.0::overdrive | OverDrive ONIX 3.0 |
| onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
| csv::thoth | Thoth CSV |
| json::thoth | Thoth JSON |
| kbart::oclc | OCLC KBART |
| bibtex::thoth | Thoth BibTeX |
| doideposit::crossref | CrossRef DOI deposit |
| onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
| marc21record::thoth | Thoth MARC 21 Record |
| marc21markup::thoth | Thoth MARC 21 Markup |
| marc21xml::thoth | Thoth MARC 21 XML |
